CN Patent

CN108236609A — 一种gpr40激动剂药物组合物及其制备方法

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2018-07-03 · 8y expired

What this patent protects

本发明涉及一种GPR40激动剂药物组合物及其制备方法。具体而言，本发明涉及的药物组合物含有2‑((S)‑6‑((2',6'‑二甲基‑4'‑(((R)‑四氢呋喃‑3‑基)氧基)‑[1,1'‑联苯]‑3‑基)甲氧基)‑2,3‑二氢苯并呋喃‑3‑基)乙酸或其可药用盐和聚乙烯吡咯烷酮，该组合物具有溶出好，稳定性好等特性。

USPTO Abstract

本发明涉及一种GPR40激动剂药物组合物及其制备方法。具体而言，本发明涉及的药物组合物含有2‑((S)‑6‑((2',6'‑二甲基‑4'‑(((R)‑四氢呋喃‑3‑基)氧基)‑[1,1'‑联苯]‑3‑基)甲氧基)‑2,3‑二氢苯并呋喃‑3‑基)乙酸或其可药用盐和聚乙烯吡咯烷酮，该组合物具有溶出好，稳定性好等特性。

Drugs covered by this patent

Patent Metadata

Patent number
CN108236609A
Jurisdiction
CN
Classification
—
Expires
2018-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.